Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Drugs Made In America Acquisition (DMAA) Income from Continuing Operations (2025)

Drugs Made In America Acquisition filings provide 1 years of Income from Continuing Operations readings, the most recent being 212958.0 for Q4 2025.

  • Quarterly Income from Continuing Operations changed N/A to 212958.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5940643.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 5940643.0 for FY2025, 2222.83% up from the prior year.
  • Income from Continuing Operations hit 212958.0 in Q4 2025 for Drugs Made In America Acquisition, down from 2184563.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 2288579.0 in Q2 2025 and bottomed at 212958.0 in Q4 2025.